Ethicon Introduces ETHIZIA Hemostatic Sealing Patch, Clinically Proven To Stop Disruptive Bleeding
Portfolio Pulse from Benzinga Newsdesk
Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIA Hemostatic Sealing Patch, designed to stop bleeding in surgeries. ETHIZIA is unique for being equally active on both sides and has shown to stop bleeding six times faster than the leading Fibrin Sealant Patch in clinical trials. It will launch in EMEA in Q1 2024, with plans for North America, APAC, and LATAM. Ethicon acquired GATT Technologies B.V. in May 2022, enhancing its portfolio with synthetic polymer technology for surgical bleeding and leak challenges.
November 15, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Ethicon division has received approval for ETHIZIA Hemostatic Sealing Patch, which is expected to enhance its surgical product offerings. The product's unique features and clinical trial results suggest a competitive advantage in the market.
The approval of ETHIZIA Hemostatic Sealing Patch is likely to have a positive impact on Johnson & Johnson's stock in the short term due to the product's innovation and potential market advantage. The clinical trial results and the unique design of the product suggest it could become a preferred choice for surgeons, potentially increasing Ethicon's market share in the surgical products sector. The acquisition of GATT Technologies B.V. and the subsequent development of ETHIZIA also demonstrate Johnson & Johnson's commitment to expanding its MedTech portfolio, which could be viewed favorably by investors.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80